Critics of the study say they are not surprised by the study’s conclusions, as oncologists make treatment decisions based on best treatment course, not money.
This study involved the engineering of CAR-T cells specific for the EGFRvIII antigen to also secrete bispecific T cell engagers (BiTEs) against wild-type EGFR.
Researchers at St Jude Children’s Research Hospital sought to determine what indicators in survivors of CNS tumors can predict the survivor’s ability to live independently as an adult.
[OncoTargets and Therapy] Management of brain metastases in patients with EGFR-mutant NSCLC is controversial. In this study, researchers find combination and sequential treatment with EGFR-TKIs, chemotherapy, and radiotherapy is beneficial.
Researchers argue that palliative care integration into treatment regimens contribute to improving the quality of life for patients in phase 1 clinical trials.
FORTIS, a phase 3 randomized study, evaluated the effects of dose intensity of the frontline fludarabine/cyclophosphamide/rituximab on progression-free and overall survival in adult patients with CLL.
Using a cohort of women from the POSH Study, researchers sought to determine risk factors for changes in weight among younger, premenopausal women receiving adjuvant chemotherapy for early-stage breast cancer.
